Se connecter S'abonner en ligne
  • Infos sociétés
  • Infos OPCVM
  • Alertes e-mail
  • Notre offre
 Langues  Par thème  Par secteur d'activité  Par pays
CAGE Bio Inc. [0]   
[03/08/2023]

CAGE Bio Inc. : CAGE Bio Announces Positive Topline Results From its Double-Blind Phase 2 Study Evaluating an Ionic Liquid formulation of 1% Tofacitinib In Patients with Atopic Dermatitis

SAN CARLOS, CA and FORT WORTH, TX / ACCESSWIRE / August 3, 2023 / CAGE Bio, Inc. hereinafter "CAGE Bio" a biotechnology company focused on developing innovative drug therapies for localized treatment of immunodermatological disorders, today announced positive results from its randomized, vehicle controlled, phase 2 study evaluating the safety and efficacy of CGB500, an ionic liquid... Lire le communiqué
 
CAGE Bio Inc. [0]   
[15/09/2022]

CAGE Bio Inc. : CAGE Bio, TAGCyx, and PeptiStar Announce Execution of a License Agreement for Development and Commercialization of TAGX-0003 for the Treatment of Immunodermatology Diseases Mediated by the IFN-Gamma Pathway

SAN CARLOS, CA and FORT WORTH, TX / ACCESSWIRE / September 15, 2022 / CAGE Bio Inc. hereinafter "CAGE Bio", a biotechnology company focused on developing innovative therapies for infection, inflammation and immunology and TAGCyx Biotechnologies Inc. hereinafter "TAGCyx", a biotechnology company developing DNA aptamer drugs based on its proprietary artificial nucleic acid base... Lire le communiqué
 


Vidéos
Gestionnaires,
Emetteurs,
Ma sélection
Les communiqués les plus lus de CAGE Bi...